About Regeneus
Regeneus is an Australian biotechnology company aiming to improve the quality of life of patients suffering from pain.
We develop regenerative medicine products that interrupt the inflammatory cascade that leads to pain in the first place. Worldwide, there are hundreds of millions of patients suffering from short-term and chronic pain. Regeneus listed on the Australian Securities Exchange (ASX) in September 2013 under the ticker code ‘RGS’.
Investment highlight
Regeneus is focused on the US$69 billion global pain market, starting with commercialising Progenza™ for osteoarthritis in Japan.
Watch the above video where new Regeneus (ASX:RGS) CEO Karolis Rosickas announces the release of the Company's Half Year Results for H1 FY21.
Latest news & insights
See below for the latest updates on the Company's activity.
Regeneus Half Year Results H1 FY21
Regeneus' (ASX:RGS) CEO Karolis Rosickas announces the release of the Company's Half Year Results for the period ending 31 December 2020. Read the full report here and the cover note here.
Regeneus to be granted new patent to target pain in Japan
Regeneus announced it has been granted a key patent for its lead stem cell technology platform Progenza™ for the treatment of pain in Japan. Read the full announcement on the ASX here.
Regeneus Quarterly Report Q2 FY21
Regeneus' (ASX:RGS) CEO Karolis Rosickas announces the release of the Company's Q2 FY21 results. Read Regeneus' Quarterly Cashflow report for the period ending 31 December 2020 here.
Subscribe to our investor newsletter
Subscribe to Regeneus' investor newsletter for the latest information and updates